solar Pana acum biologie trial turoctocog guardian 2 supplementary table s4 Om de afaceri rețea de sârmă ghimpată tăcere
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device - ScienceDirect
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study - Escuriola Ettingshausen - - Haemophilia -
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa - Santagostino - 2014 - Haemophilia - Wiley Online Library
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 p
Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A - Lentz - 2016 - Haemophilia - Wiley Online Library
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Longâ•'term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia
PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review - Hassan - 2018 - Journal of Thrombosis and Haemostasis - Wiley Online Library
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
Supplementary Appendix 2020.01.27 R2
Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results - John - 2020 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
PDF) von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A